Lisinopril
Brand names: Zestril, Carace
Lisinopril is a long-acting angiotensin-converting enzyme (ACE) inhibitor used for hypertension, heart failure, after myocardial infarction and to slow progression of diabetic nephropathy.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It inhibits ACE, reducing conversion of angiotensin I to the vasoconstrictor angiotensin II and decreasing aldosterone secretion, which lowers vascular resistance and reduces sodium and water retention.
Prescribing in practice
- It is contraindicated in pregnancy and in anyone with a history of ACE-inhibitor-associated angioedema, which can be life-threatening if it affects the airway.
- First-dose hypotension can occur, especially in volume-depleted patients or those on high-dose diuretics, so initiation should be cautious in these groups.
- It can cause hyperkalaemia and a persistent dry cough, the latter being a common reason for switching to an ARB.
Monitoring
Check renal function and serum potassium before starting and after initiation or dose increase, and monitor blood pressure for response.
Counselling the patient
- Stop the medicine and seek urgent help if your lips, tongue, face or throat swell.
- A persistent dry cough is a known side effect; tell your doctor if it is troublesome.
- Do not take this medicine if you are or could become pregnant.
Evidence & guidelines
ACE inhibitors such as lisinopril are recommended first-line in NICE guidance for hypertension in younger or diabetic patients and for heart failure with reduced ejection fraction, with mortality benefit shown across major heart-failure and post-infarction trials.
Reference: NICE NG136/NG106; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines